Cesar Simbaqueba Clavijo
CEMIPLIMAB SAFETY IN PATIENTS WITH ADVANCED CUTANEOUS (CSCC) AND NON-SMALL CELL LUNG CANCER (NSCLC). THE MD ANDERSON EXPERIENCE
Hsu Chih-Chien
QUALITY OF LIFE IN ADVANCED LUNG CANCER PATIENTS RECEIVING IMMUNOTHERAPY
Norman Brito-Dellan
“CANCER AND THE IMMUNE SYSTEM”: THE USE OF MEDICAL ANIMATION TO EDUCATE ON IMMUNO-ONCOLOGY AND IMMUNE-RELATED ADVERSE EVENTS
Chia-Li Siao
UNMET CARE NEEDS AND RELATIVE FACTORS IN PATIENTS WITH CANCER ON IMMUNOTHERAPY:A CROSS-SESSIONAL STUDY
Wenxin Chen
CLUSTERS OF MULTI-ORGAN TOXICITIES ARE ASSOCIATED WITH IMPROVED SURVIVAL AMONG IMMUNE CHECKPOINT INHIBITOR RECIPIENTS: A POPULATION-LEVEL ANALYSIS
Yin Ting Cheung
IMMUNE-RELATED ADVERSE EVENTS ASSOCIATED WITH PD-1/PD-L1 INHIBITORS IN METASTATIC NSCLC PATIENTS: A SINGLE-CENTER STUDY FROM HONG KONG
Cesar A. Virgen
MOGAMULIZUMAB-ASSOCIATED MYOSITIS WITH AND WITHOUT MYASTHENIA GRAVIS AND/OR MYOCARDITIS IN PATIENTS WITH T-CELL LYMPHOMA
Christina H. Ruhlmann
A MULTICENTER RETROSPECTIVE COHORT STUDY INVESTIGATING IMMUNE-RELATED THYROID TOXICITY IN ADJUVANT MELANOMA PATIENTS TREATED WITH A PD-1 INHIBITOR.
Nabil Elhadi Omar
A Real-world pharmacovigilance analysis of the incidence and characteristics of fatal immune-related adverse events of Immune checkpoint inhibitors
Luwei Li
A correlation study between gut microbes and immune checkpoint inhibitors in the treatment of non-small cell lung cancer